Introduction
============

Hepatocellular carcinoma (HCC) is one of the main causes of tumor-associated mortality, being the fifth most common malignancy worldwide ([@b1-or-41-05-2855]). In 2018, the number of new cases and liver cancer-associated mortalities was 841,080 and 781,631, respectively, worldwide ([@b2-or-41-05-2855]). Many risk factors, including dietary aflatoxin exposure ([@b3-or-41-05-2855]), hepatitis B and C virus (HBV) infection ([@b4-or-41-05-2855]) and cirrhosis, contribute to the initiation and progression of HCC. To date, many diagnostic and treatment procedures, including ultrasound, computed tomography, liver resection, liver transplantation, radiofrequency, thermal and non-thermal ablation, trans-arterial chemoembolization ([@b5-or-41-05-2855]), immunotherapies and therapeutic cancer vaccines ([@b4-or-41-05-2855]), have been used for patients with HCC. However, the prognosis of HCC is remains poor and the 5-year relative survival rate is \~12% due to tumor metastasis and recurrence ([@b6-or-41-05-2855],[@b7-or-41-05-2855]). Due to the characteristics of systemic disease, the evolution and progression of HCC involves deregulation of genes, cells and tissues ([@b1-or-41-05-2855]). Therefore, it is crucial to identify novel biomarkers that may be involved in the course of tumor metastasis and recurrence, for early diagnosis and recurrence prediction for HCC.

Phospholipase C (PLC) is encoded by four genes, *PLCA, PLCB, PLCC* and *PLCD*, and is involved in the pathogenesis of several bacterial infections, including *Clostridium perfringens, Listeria monocytogene*, and *Pseudomonas aeruginosa* ([@b8-or-41-05-2855],[@b9-or-41-05-2855]). The activity of PLCA and PLCB in *L. monocytogenes* appears to overlap in the course of intracellular infection ([@b10-or-41-05-2855]). In *Listeria*, three genes, *PLCA, PLCB* and *PLCC*, are clustered together on the same chromosome, whereas the *PCLD* gene is located in another region ([@b11-or-41-05-2855],[@b12-or-41-05-2855]). Under the transcriptional control of PrfA regulator, *PLCA, PLCB* and *HLY* (encoding listeriolysin O precursor) have a role encoding the Listeria Pathogenicity Island 1, leading to the escape from endocytic and secondary vacuoles ([@b13-or-41-05-2855]--[@b15-or-41-05-2855]). *PLCB* isoforms in mice include *PLCB1, PLCB2, PLCB3* and *PLCB4*, which are stimulated by G protein activation (Gα~q/11~ and/or Gβγ) ([@b16-or-41-05-2855],[@b17-or-41-05-2855]). The roles of PLCB isoforms in immune defense and escape, and their functions in tumors are currently being investigated. *PLCB1* has been reported to be associated with HCC prognosis in tumor proliferation ([@b1-or-41-05-2855]) and an aberrant expression pattern has been reported in patients with schizophrenia ([@b18-or-41-05-2855]). The *PLCB2* and *PLCB4* genes were found to be differentially expressed in human breast cancer MCF-7 cells, and to be associated with multidrug resistance using RNA-seq technology ([@b19-or-41-05-2855]). PLCB3 has been reported to be regulated by multiple protein kinases and to control hormonal signaling ([@b20-or-41-05-2855]).

HBV infection is regarded as a main risk factor for the development of HCC ([@b4-or-41-05-2855]). HBV is classified into ten genotypes, from A to J, and \>40 associated sub-genotypes ([@b21-or-41-05-2855]). The 10 genotypes are based on an intergroup divergence of ≥8% in the complete nucleotide sequence; whereas the sub-genotypes are based on a divergence of 4--7.5% ([@b22-or-41-05-2855],[@b23-or-41-05-2855]). Notably, genotypes A and B are associated with earlier hepatitis B e antigen seroconversion, less active liver disease, and a slower rate of progression to cirrhosis and HCC compared with genotypes C and D ([@b24-or-41-05-2855]--[@b27-or-41-05-2855]).

Some PLCB isoforms have been explored with regard their associations with tumor development; therefore, the present study aimed to explore the association between four *PLCB* genes and HCC.

Materials and methods
=====================

### Patient data collection

The GSE14520 dataset was used for analysis ([ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520](ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520); accessed June 10th, 2018) ([@b28-or-41-05-2855],[@b29-or-41-05-2855]). This dataset contains two platforms: GPL571 (GeneChip^®^ Human Genome U133A 2.0 Array; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and GPL3921 (GeneChip^®^ HT Human Genome U133 Array Plate Set; Thermo Fisher Scientific, Inc.). To avoid a batch effect, patients from GPL3921 were used. Patients with HBV infection were used, including a total of 212 patients. In addition, patient survival, including overall survival (OS) and recurrence-free survival (RFS), validated findings in the GSE14520 dataset using the Gene Expression Profiling Interactive Analysis (GEPIA; [gepia.cancer-pku.cn/index.html](gepia.cancer-pku.cn/index.html); accessed June 10th, 2018) website with data from The Cancer Genome Atlas (TCGA) database ([@b30-or-41-05-2855]).

### Gene, protein and tissue expression, and the body map

Gene expression, the body map and transcripts per million of the *PLCB* genes were collected from the GEPIA website ([gepia.cancer-pku.cn/index.html](gepia.cancer-pku.cn/index.html); accessed June 12th, 2018). Tissue and protein expression of the *PLCB* genes were collected from the GTEx portal ([gtexportal.org/home/](gtexportal.org/home/); accessed June 12th, 2018) ([@b31-or-41-05-2855]) and The Human Protein Atlas ([proteinatlas.org/](proteinatlas.org/); accessed June 12th, 2018) ([@b32-or-41-05-2855]) websites, respectively.

### Gene set enrichment analysis (GSEA)

GSEA ([software.broadinstitute.org/gsea/index.jsp](software.broadinstitute.org/gsea/index.jsp)) was performed to explore potential mechanisms that PLCB genes are involved in, including biological processes and metabolic pathways. Datasets of c2.cp.kegg.v6.1.symbols.gmt, c5.bp.b6.1.symbols.gmt, c5.cc.v6.1.symbols.gmt, c5.mf.v6.1.symbols.gmt and c5.all.v6.1.symbols.gmt were used to analyze statistically significant Gene Ontology (GO) terms, including biological process (BP), cellular component (CC), and molecular function (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ([@b33-or-41-05-2855],[@b34-or-41-05-2855]).

### Association and interaction analysis

The Pearson correlation matrix among PLCB genes was constructed using R version 3.5.0 ([r-project.org/](r-project.org/)). Pearson correlation and associations between PLCB gene expression and tumor stage were validated using the GEPIA website. The co-expression interactive network of gene-gene interactions was constructed using the geneMANIA plugin of Cytoscape software version 3.6.0 ([@b35-or-41-05-2855],[@b36-or-41-05-2855]). The protein-protein interaction (PPI) network was constructed using the STRING ([string-db.org/cgi/input.pl](string-db.org/cgi/input.pl), accessed June 20th, 2018) website ([@b37-or-41-05-2855]). GO enrichment analysis was visualized using the BiNGO plugin of Cytoscape software version 3.6.0 ([@b38-or-41-05-2855]).

### Diagnostic and prognostic analysis and stratified, joint-effect analysis

Diagnostic receiver operating characteristic (ROC) curves were constructed using the expression of PLCB genes in tumor and non-tumor tissues. Gene expressions were categorized into two groups of low and high expression at a cut-off value of median expression levels. OS and RFS were calculated using the Kaplan-Meier and Cox proportional hazards regression models. Statistically significant clinical factors were adjusted for multivariate Cox models. Then, prognosis-associated genes were further stratified for analysis by clinical factors. In addition, prognosis-associated genes were combined for a joint-effect analysis with α-fetoprotein (AFP) based low and high expression.

### Expression model and nomogram construction

To further explore prognosis-associated genes for HCC survival, expression models for OS and RFS prediction were constructed. Gene expression, patient survival status, expression heatmaps and prognostic ROC curves were constructed in the model ([@b39-or-41-05-2855]--[@b42-or-41-05-2855]). Nomograms for OS and RFS were also constructed using clinical factors and genes to predict patient survival probability at 1, 3 and 5 years.

### Genome-wide analysis of prognosis-associated genes

Prognosis-associated genes were further explored in genome-wide analysis. A cut-off value of 0.4 was determined for further analysis. The cut-off 0.4 can filter a lot of genes with weak relationships with PLCB1 and leads to a better presentation of GO and pathway results compared with other cut-off values. Gene-gene interactions, and BP, CC and MF were constructed using Cytoscape software.

### Statistical analysis

Unpaired t test was used to analyze expressions of PLCBs in tumor and non-tumor tissues. Box plots and survival plots were generated using GraphPad software version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). Survival analyses were performed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA). Median survival time and log-rank P-value were calculated by the Kaplan-Meier method, and the 95% confidence interval (CI) and hazard ratio (HR) were calculated by univariate and multivariate Cox proportional hazards regression models, respectively. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographic and clinical characteristics

Data from 212 patients (GSE14520) with HBV-associated HCC were used in the study. AFP, BCLC stage, tumor size and cirrhosis were associated with OS (P=0.049, P\<0.0001, P=0.002 and P=0.041, respectively). Gender, cirrhosis and BCLC stage were associated with RFS (P=0.002, P=0.036 and P\<0.0001, respectively). Other factors were not associated with prognosis (P\>0.05; [Table SI](#SD1-or-41-05-2855){ref-type="supplementary-material"}).

### Gene, protein, tissue expressions and transcription analysis

*PLCB1* and *PLCB3* were highly expressed in tumor tissues compared with normal tissue, whereas *PLCB2* had the opposite result (all P≤0.05; [Fig. 1A-C](#f1-or-41-05-2855){ref-type="fig"}). However, there was no difference in *PLCB4* expression between the tumor and normal tissue ([Fig. 1D](#f1-or-41-05-2855){ref-type="fig"}). Transcriptional analysis indicated that *PLCB1, PLCB3* and *PLCB4* consistently exhibited higher transcripts per millions in tumor tissues compared with normal tissues ([Fig. 1E-H](#f1-or-41-05-2855){ref-type="fig"}). Tissue and protein expression of the *PLCB* genes were collected from the GTEx portal.

Gene expression levels in 212 patients with HBV-HCC (GSE14520) indicated that there were significant differences in *PLCB1* and *PLCB2* expression between tumor and non-tumor tissues, whereas there was not difference in *PLCB3* and *PLCB4* between the samples ([Fig. 2A](#f2-or-41-05-2855){ref-type="fig"}). In addition, when tumor samples were divided into high and low expression groups using the median as the cutoff there were significant differences in *PLCB1, PLCB2* and *PLCB4*; whereas *PLCB3* did not exhibit significance ([Fig. 2B](#f2-or-41-05-2855){ref-type="fig"}). The bodymap distribution of PLCB genes in different organs is shown in [Fig. S1](#SD1-or-41-05-2855){ref-type="supplementary-material"}. Protein expression levels demonstrated that PLCB2 is the most highly expressed of the PLCB family ([Fig. S2](#SD1-or-41-05-2855){ref-type="supplementary-material"}). The different tissue expression levels of PLCB family members demonstrated that all were expressed at low levels in the liver ([Fig. S3](#SD1-or-41-05-2855){ref-type="supplementary-material"}).

### Diagnostic and prognostic analysis

In the diagnostic analysis of PLCB genes, PLCB1 and PLCB2 exhibited diagnostic value for HCC, while PLCB3 showed potential diagnostic value \[P\<0.0001, P\<0.0001 and P=0.018, respectively; area under the curve (AUC), 0.869, 0.836 and 0.567, respectively; [Fig. 3A-C](#f3-or-41-05-2855){ref-type="fig"}\]. However, PLCB4 did not have any diagnostic value (P=0.811; [Fig. 3D](#f3-or-41-05-2855){ref-type="fig"}). In the combined diagnostic analysis for PLCB1, PLCB2 and PLCB3, the combinations of PLCB1 + PLCB2, PLCB1 + PLCB3, and PLCB1 + PLCB2 + PLCB3 exhibited diagnostic value for HCC with an advantage over PLCB1, PLCB2 or PLCB3 alone (AUC, 0.905, 0.877 and 0.920, respectively; all P\<0.05; [Fig. 3E, F and H](#f3-or-41-05-2855){ref-type="fig"}). The combination of PLCB2 and PLCB3 exhibited potential diagnostic value for HCC (AUC, 0.604; P=0.0003; [Fig. 3G](#f3-or-41-05-2855){ref-type="fig"}). In the prognostic analysis ([Figs. 4](#f4-or-41-05-2855){ref-type="fig"} and [5](#f5-or-41-05-2855){ref-type="fig"}), only PLCB1 expression was associated with patient OS at 1-, 3- and 5-years (all AUC \>0.6; [Fig. 4A, E and I](#f4-or-41-05-2855){ref-type="fig"}). In addition, PLCB1 expression was associated with patient RFS at 3- and 5-years (both AUC \>0.6; [Fig. 5E and I](#f5-or-41-05-2855){ref-type="fig"}).

In the univariate analysis ([Tables I](#tI-or-41-05-2855){ref-type="table"} and [II](#tII-or-41-05-2855){ref-type="table"}; [Fig. 6](#f6-or-41-05-2855){ref-type="fig"}), *PLCB1* expression was associated with OS (crude P=0.002; [Fig. 6A](#f6-or-41-05-2855){ref-type="fig"}); *PLCB1* and *PLCB3* expression was associated with RFS (crude P=0.001 and P=0.042, respectively; [Fig. 6E and G](#f6-or-41-05-2855){ref-type="fig"}). In the multivariate analysis, *PLCB1* expression was associated with OS and RFS (adjusted P=0.002 and 0.001, respectively; [Tables I](#tI-or-41-05-2855){ref-type="table"} and [II](#tII-or-41-05-2855){ref-type="table"}). Other genes were not associated with prognosis (adjusted P\>0.05; [Tables I](#tI-or-41-05-2855){ref-type="table"} and [II](#tII-or-41-05-2855){ref-type="table"}).

### Stratified and joint-effect survival analysis

Stratification analysis was performed for *PLCB1* on OS and RFS. Male gender, age \<60 years, chronic carrying of HBV, cirrhosis, single nodular, AFP levels \<300 ng/ml, and A stage in the BCLC staging system were associated with OS and RFS (all adjusted P≤0.05; [Table III](#tIII-or-41-05-2855){ref-type="table"}). Tumor size \<5 cm was associated with OS and any group of tumor size was associated with RFS (all adjusted P≤0.05; [Table III](#tIII-or-41-05-2855){ref-type="table"}).

In the joint-effect analysis (OS/RFS: group 1/I, AFP low + PLCB1 low; group 2/II, AFP low + PLCB1 high, and AFP high + PLCB1 low; groups 3/III, AFP high + PLCB1 high), when combining *PLCB1* and AFP, prognostic significance was observed among the three groups for OS (adjusted P=0.008; [Table IV](#tIV-or-41-05-2855){ref-type="table"}); group 3 exhibited the worst prognosis \[adjusted P=0.002, adjusted HR (95% CI)=4.382 (1.703--11.276); [Table IV](#tIV-or-41-05-2855){ref-type="table"}\]. Prognostic significance was not observed among the three groups in RFS (adjusted P=0.075; [Table IV](#tIV-or-41-05-2855){ref-type="table"}). However, group III exhibited the worst prognosis \[adjusted P=0.045, adjusted HR (95% CI)=1.670 (1.012--2.755); [Table IV](#tIV-or-41-05-2855){ref-type="table"}\].

### GSEA

Both diagnostic- and prognostic-associated genes were explored to investigate the mechanisms that PLCBs are involved in. Enriched GO terms and KEGG pathways annotated with *PLCB1* included 'G protein coupled receptor activity', 'sodium channel activity', 'extracellular ligand gated ion channel activity' and 'taste transduction pathway', among others ([Fig. 7](#f7-or-41-05-2855){ref-type="fig"}). Enriched GO terms and KEGG pathways annotated with *PLCB2* included 'mRNA processing', 'cell division', 'cell cycle checkpoints', 'DNA repair', 'PPAR signaling pathway', 'metabolism of xenobiotics by cytochrome P450' and 'adipocytokine signaling pathway' among others ([Fig. 8](#f8-or-41-05-2855){ref-type="fig"}).

### Expression model and nomogram construction

An expression model was constructed for OS and RFS prognosis prediction ([Fig. 9](#f9-or-41-05-2855){ref-type="fig"}). PLCB1 expression, OS and RFS survival status, and *PLCB1* expression heatmaps are shown in [Fig. 9A](#f9-or-41-05-2855){ref-type="fig"}, and prognostic ROC curves demonstrated that PLCB1 expression has prognostic value for OS and RFS ([Fig. 9B and C](#f9-or-41-05-2855){ref-type="fig"}).

Furthermore, nomograms were constructed for clinical factors and *PLCB1*. High expression always led to low points. The same points indicated a higher probability of survival at 1 year, yet a lower probability of survival at 5 years for both OS and RFS. Survival probability at 3 years was seated in the middle ([Fig. 10](#f10-or-41-05-2855){ref-type="fig"}).

### Interaction and co-expression networks and enrichment analysis

Associations between gene expression and TNM stage (I, II, III) were visualized; *PLCB1* gene expression of 212 HBV-HCC was significantly different in early (I, II) stages compared with advanced (III) stage in (P≤0.01; [Fig. 11A](#f11-or-41-05-2855){ref-type="fig"}). Associations between gene expressions and TNM stage (I, II and III) in GEPIA indicated that *PLCB1* expression was different in different tumor stages ([Fig. 11B](#f11-or-41-05-2855){ref-type="fig"}). Gene-gene co-expression interactions and PPI networks demonstrated interactions between PLCB members ([Fig. 11C and D](#f11-or-41-05-2855){ref-type="fig"}). The Pearson correlation matrix showed an association between PLCB members ([Fig. 11E](#f11-or-41-05-2855){ref-type="fig"}).

Furthermore, enriched GO terms are presented in [Fig. S4A-C](#SD1-or-41-05-2855){ref-type="supplementary-material"}. KEGG pathways that PLCB members are involved in are presented in [Fig. S5](#SD1-or-41-05-2855){ref-type="supplementary-material"}. All members were involved in diacylglycerol and IP3 metabolism and finally induced sustained angiogenesis, thus evading apoptosis and proliferation effects.

### Analysis of PLCB1 and associated genes genome-wide

Pearson correlation analysis was performed for PLCB1 genome-wide. A total of 53 genes were identified at r≥0.4. Gene-gene interaction analysis was constructed and presented in [Fig. 12](#f12-or-41-05-2855){ref-type="fig"}. Networks of BP, CC and MF terms were constructed ([Fig. 13](#f13-or-41-05-2855){ref-type="fig"}). Enriched GO terms and KEGG pathways annotated by PLCB1 and correlated genes are presented in [Table V](#tV-or-41-05-2855){ref-type="table"}.

### Validation of prognostic values of PLCB genes

PLCB genes were further validated in GEPIA for OS and RFS ([Fig. 14](#f14-or-41-05-2855){ref-type="fig"}). *PLCB1* and *PLCB2* were associated with OS (P=0.0075 and P=0.041, respectively; [Fig. 14A and B](#f14-or-41-05-2855){ref-type="fig"}). In addition, *PLCB1* and *PLCB4* were associated with RFS (P\<0.0001 and P\<0.018, respectively; [Fig. 14E and H](#f14-or-41-05-2855){ref-type="fig"}). Other genes were not associated with OS or RFS (all P\>0.05; [Fig. 14](#f14-or-41-05-2855){ref-type="fig"}). Pearson correlation in GEPIA ([Fig. 15](#f15-or-41-05-2855){ref-type="fig"}) indicated that *PLCB1* was positively correlated with *PLC3* and *PLCB4*, while *PLCB3* was positively correlated with *PLCB4*, which is consistent with [Fig. 11E](#f11-or-41-05-2855){ref-type="fig"}.

Discussion
==========

In the current study, it was identified that *PLCB1* and *PLCB2* genes are differently expressed in tumor and normal tissues. *PLCB1* and *PLCB2* have diagnostic value for HCC, while *PLCB3* has potential diagnostic value for HCC. Combinations of these genes have an advantage over *PLCB1, PLCB2* or *PLCB3* alone with regard to HCC diagnosis. In addition, *PLCB1* has prognostic value of OS and RFS for HCC. Combining *PLCB1* and AFP had an advantage over PLCB1 alone for OS and RFS. GSEA indicated that PLCB1 and PLCB2 were involved in 'G protein coupled receptor activity', 'sodium channel activity', 'cell division', 'cell cycle checkpoint', 'DNA repair', 'PPAR signaling pathway', 'metabolism of xenobiotics by cytochrome P450' and 'adipocytokine signaling pathway', among others. Nomograms and gene expression models were constructed for HCC prognosis prediction. The validation of the prognostic values of PLCB genes revealed that *PLCB1* and *PLCB2* were associated with OS, and *PLCB1* and *PLCB4* were associated with RFS.

PLC proteins are key enzymes that metabolize inositol lipids and have a pivotal role in multiple transmembrane signaling transduction pathways that modulate a series of cellular processes, including cell proliferation and mobility ([@b16-or-41-05-2855]). In mammalian cells, there are four PLCB isoforms: PLCB1, PLCB2, PLCB3 and PLCB4. PLCB2 and PLCB3 are activated by Gβγ dimers, which are released upon the activation of Gα protein coupled receptor families ([@b43-or-41-05-2855]). PLCB2 can also be activated by Rho family members of monomeric G proteins, with the strongest activation by Rac1; these participate in the cytoskeletal rearrangements that accompany cell mobility ([@b44-or-41-05-2855]).

The PLCB1 enzyme is encoded by the *PLCB1* gene, which is located at chromosome of 20p12 ([@b1-or-41-05-2855]). It was originally identified as a G protein coupled receptor-associated PLCB isoform that is able produce inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphophate ([@b45-or-41-05-2855]). The deregulation of signaling transduction pathways always leads to advantages for tumor patients ([@b1-or-41-05-2855]). *PLCB1* is activated by Gα and induces a variety of events, which may increase the total intracellular calcium levels ([@b46-or-41-05-2855]); one possible result of this process is aberrant proliferation in the cell ([@b1-or-41-05-2855]). PLCB1 has been reported to have a role in promoting cell cycle progression by targeting cyclin-cyclin kinase complexes ([@b47-or-41-05-2855]).

In addition, *PLCB1* has been documented to have a pivotal role in myoblast differentiation, regulating the delayed differentiation of skeletal muscle in myotonic dystrophy myoblasts ([@b48-or-41-05-2855]). *PLCB1* may also reduce cell damage under oxidative conditions and prevent α-synuclein aggregation ([@b49-or-41-05-2855]). The amplification of *PLCB1* increased K562 cell viability and enables cells to evade apoptosis ([@b50-or-41-05-2855],[@b51-or-41-05-2855]); the overexpression of *PLCB1* keeps Swiss 3T3 cells in the S phase of the cell cycle ([@b52-or-41-05-2855]). Li *et al* ([@b1-or-41-05-2855]) reported that upregulated *PLCB1* expression is associated with tumor cell proliferation and infers a poor prognosis for HCC. The present study revealed that high expression has is undesirable for HCC prognosis (OS and RFS), which is consistent with the results of Li *et al* ([@b1-or-41-05-2855]). Furthermore, *PLCB1* had diagnostic value for HCC.

*PLCB2* mediates mitogenic, proliferative and migratory events by interacting with heterotrimeric and monomeric G proteins, and can interact with γ-synuclein to regulate G protein activation ([@b43-or-41-05-2855]). Bertagnolo *et al* ([@b53-or-41-05-2855]) reported that *PLCB2* induces cell cycle transition from G0/G1 to the S/G2/M phases, which is critical for tumor progression, without affecting cell cycle-associated enzymes. They also indicate that *PLCB2*, by modifying the phospholipase pool, may be responsible for the inositol lipid-associated modifications of the cytoskeleton architecture that occur in the course of division, motility and invasion of tumor cells ([@b53-or-41-05-2855]). The current findings with regard to the role of *PLCB2* in the cell cycle and cell division are consistent with the results of Bertagnolo *et al* ([@b53-or-41-05-2855]).

*PLCB2* has been reported to promote mitosis and the migration of human breast cancer-derived cells ([@b54-or-41-05-2855]), is highly expressed in breast cancer and associated with poor prognosis ([@b55-or-41-05-2855]); however, little is known about HCC *PLCB2* expression, and the role in HCC diagnosis and prognosis. In the current study, *PLCB2* expression as not associated with HCC prognosis, but may be a diagnostic signature for HCC.

*PLCB3* is located on chromosome 11q13 in the vicinity of the multiple endocrine neoplasia type 1 gene; its loss leads to the development of neuroendocrine tumors ([@b56-or-41-05-2855]). The transfection of *PLCB3* to a human endocrine pancreatic tumor cell line can induce the activation of the human mismatch repair protein 3 gene ([@b56-or-41-05-2855]). *PLCB3* interacts with Na(+)/H(+) exchange regulatory cofactor NHERF-1, providing a structural basis for CXCR2 signaling in pancreatic cancer ([@b57-or-41-05-2855]). Hoeppner *et al* ([@b58-or-41-05-2855]) identified a novel role for *PLCB3*, functioning as a negative regulator of vascular endothelial growth factor-mediated vascular permeability by regulating intracellular Ca^2+^ release. *PLCB3* may have a tumor suppressor role via SHP-1-mediated dephosphorylation of Stat5 ([@b59-or-41-05-2855]). Ju *et al* ([@b60-or-41-05-2855]) reported that PLCB and G~qα~ may have important roles in scar remodeling, cardiac hypertrophy and fibrosis following myocardial infarction rat hearts. In the present study, *PLCB3* expression exhibited potential diagnostic value for HCC and without association with HCC prognosis. *PLCB3* may have a weak role in HCC if at all, which requires further investigation.

Compared with other PLCB genes, *PLCB4* is less well characterized, and associations between *PLCB4* and cancer are unclear. The expression of *PLCB4* and *PLCB3* was previously explored in Purkinje cell subsets of the mouse cerebellum ([@b61-or-41-05-2855]). *PLCB4* and *PLCB3* are differentially expressed in microarray databases of non-small cell lung cancer, but neither are associated with the prognosis and development of lung cancer ([@b62-or-41-05-2855]). Orchel *et al* ([@b63-or-41-05-2855]) reported that *PLCB4* is differentially expressed in 50 endometrium samples from women with endometrial cancer, but is not associated with the treatment of endometrial cancer. Furthermore, the present study did not find any association between *PLCB4* and HCC. Therefore, further studies are required to explore the relationship between *PLCB4* expression and malignancy.

The findings of the present study indicate that *PLCB1* expression was associated with OS, whereas *PLCB1* and *PLCB3* expression was associated with RFS in univariate analysis. In multivariate analysis, *PLCB1* expression was associated with OS and RFS. Multivariate cox analysis contains several significant clinicopathological characteristics, which produces new adjusted results and conclusions. In addition, *PLCB1* expression was associated with OS, whereas *PLCB1* and *PLCB3* expression was associated with RFS in univariate analysis. However, *PLCB1* expression was associated with OS and RFS in multivariate analysis. Different results may be due to varied clinicopathological characteristics in the GSE14520 and TCGA dataset. Of course, HBV is a pivotal factor associated with HCC.

There are some limitations to the present study that should be recognized. Firstly, larger sample cohorts are required to validate these findings. Additionally, the results are based on a HBV-associated HCC population; therefore, further explorations are needed in a study including HBV-infected and non-infected patients. Finally, functional trials are required to further explore the roles of PLCB genes in HCC initiation, development, metastasis, proliferation and angiogenesis. BCLC stage is an important factor associated with HCC and treatments concerning BCLC stage should mentioned in the material section.

The present study demonstrated that the *PLCB1* and *PLCB2* genes are differentially expressed between tumor and normal tissues and have diagnostic values for HCC. *PLCB3* has a potential diagnostic value for HCC. The combinations of these genes have an advantage over *PLCB1, PLCB2* or *PLCB3* used alone for HCC diagnosis. In addition, *PLCB1* has OS and RFS prognostic value for HCC. Combining *PLCB1* and AFP was advantageous over *PLCB1* alone for predicting OS and RFS. Nomogram and gene expression models were used to construct and predict HCC prognosis. GO terms and metabolic pathways associated with *PLCB1* and *PLCB2* are include 'G protein coupled receptor activity', 'cell division', 'cell cycle checkpoint', 'DNA repair', 'PPAR signaling pathway' and 'metabolism of xenobiotics by cytochrome P450'. Validation of the prognostic value of the PLCB genes revealed that *PLCB1, PLCB2* and *PLCB4* are associated with HCC prognosis.
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![Relative mRNA expressions and transcriptional levels of PLCB1-4 in tumor and non-tumor tissues. Relative mRNA expressions of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4 in tumor and non-tumor tissues Transcriptional levels of (E) PLCB1, (F) PLCB2, (G) PLCB3 and (H) PLCB4 in tumor and non-tumor tissues. PLCB, phospholipase C β.](OR-41-05-2855-g00){#f1-or-41-05-2855}

![Relative mRNA expressions of PLCB1-4 in tumor and normal tissues and low, high expression groups. (A) Relative mRNA expressions of PLCB1-4 in tumor and normal tissues; (B) Relative mRNA expressions of PLCB1-4 in low and high expression groups. PLCB, phospholipase C β.](OR-41-05-2855-g01){#f2-or-41-05-2855}

![Diagnostic ROC curves of PLCB1-4. A-D: Diagnostic ROC curves of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4; Diagnostic ROC curves of combination of (E) PLCB1 and PLCB2, (F) PLCB1 and PLCB3, (G) PLCB2 and PLCB3, and (H) PLCB1, PLCB2 and PLCB3. ROC, receiver operating characteristics; PLCB, phospholipase C β; AUC, area under the curve; CI, confidence interval.](OR-41-05-2855-g02){#f3-or-41-05-2855}

![Overall survival ROC curves of PLCB1-4 at 1, 3 and 5 years. ROC curves of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4 at 1 year; ROC curves of (E) PLCB1, (F) PLCB2, (G) PLCB3 and (H) PLCB4 at 3 years; ROC curves of (I) PLCB1, (J) PLCB2, (K) PLCB3 and (L) PLCB4 at 5 years. PLCB, phospholipase C β; ROC, receiver operating characteristics.](OR-41-05-2855-g03){#f4-or-41-05-2855}

![Recurrence-free survival ROC curves of PLCB1-4 at 1, 3 and 5 years. ROC curves of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4 at 1 year; ROC curves of (E) PLCB1, (F) PLCB2, (G) PLCB3 and (H) PLCB4 at 3 years; ROC curves of (I) PLCB1, (J) PLCB2, (K) PLCB3 and (L) PLCB4 at 5 years. PLCB, phospholipase C β; ROC, receiver operating characteristics.](OR-41-05-2855-g04){#f5-or-41-05-2855}

![Overall survival and recurrence-free survival analysis plots of PLCB1-4. Overall survival analysis plot of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4; recurrence-free survival analysis plot (E) PLCB1, (F) PLCB2, (G) PLCB3 and (H) PLCB4; joint-effects analysis of (I) α-fetoprotein and (J) PLCB1 for overall survival and recurrence-free survival. Group 1, AFP low expression and PLCB1 low expression; Group 2, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group 3, AFP high expression and PLCB1 high expression; Group I, AFP low expression and PLCB1 low expression; Group II, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group III, AFP high expression and PLCB1 high expression. PLCB, phospholipase C β.](OR-41-05-2855-g05){#f6-or-41-05-2855}

###### 

Gene set enrichment analysis results of *phospholipase C β1* gene. Results of gene ontologies: (A) G-protein coupled receptor activity; (B) sodium channel activity; (C) neutotransmitter receptor activity; (D) extracellular ligand gated ion channel activity. GO, gene ontology; NES, normalized enrichment score; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes. Gene set enrichment analysis results of *phospholipase C β1* gene. Results of gene ontologies: (E) sodium ion transmembrane transporter; (F) passive transmembrane transporter; (G) gated channel activity; (H) cation channel activity; (I) monovalent inorganic cation transmembrane transporter activity; (J) excitatory extracellular ligand gated ion channel activity; (K) ligand gated channel activity. (L) Taste transduction KEGG pathway. GO, gene ontology; NES, normalized enrichment score; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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###### 

Gene set enrichment analysis results of *phospholipase C β2* gene. Results of gene ontologies: (A) mRNA processing; (B) cell division; (C) negative regulation of mitotic cell cycle; (D) cell cycle checkpoint. GO, gene ontology; NES, normalized enrichment score; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPAR peroxisome proliferator-activated receptor. Gene set enrichment analysis results of *phospholipase C β2* gene. Results of gene ontologies: (E) DNA repair; (F) negative regulation of cell cycle phase transition (G) mitotic nuclear division; (H) iron ion binding. Results of KEGG pathways: (I) metabolism of xenobiotics by cytochrome P450; (J) PPAR signaling pathway; (K) adipocytokine signaling pathway; (L) steroid hormone biosynthesis. GO, gene ontology; NES, normalized enrichment score; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPAR peroxisome proliferator-activated receptor.
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![Expression model constructed using *PLCB1* gene. (A) Expression model including expression, overall survival status, recurrence-free survival status and heatmap. (B) Time dependent ROC curves of overall survival at 1, 3- and 5- years. (C) Time dependent ROC curves of recurrence-free survival at 1, 3- and 5-years. PLCB1, phospholipase C β1; ROC, receiver operating characteristics; AUC, area under the curve.](OR-41-05-2855-g12){#f9-or-41-05-2855}

![Nomograms constructed using overall survival and recurrence-free survival-related clinical factors and genes. (A) Nomogram of OS-associated genes and clinical factors. (B) Nomogram of RFS-associated genes and clinical factors. BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; PLCB1, phospholipase C β1; OS, overall survival; RFS, recurrence-free survival.](OR-41-05-2855-g13){#f10-or-41-05-2855}

![Scatter plots, matrix and interaction networks analysis. (A) Scatter plot and (B) violin plot of *PLCB1* expressions. (C) Co-expression network of PLCB1-4 genes. (D) Protein-protein interaction network of PLCB1-4. (E) Pearson correlation matrix of PLCB1-4. PLCB, phospholipase C β.](OR-41-05-2855-g14){#f11-or-41-05-2855}

![Co-expression network of *PLCB1* gene with correlation-associated genes in genome-wide analysis. PLCB1, phospholipase C β1.](OR-41-05-2855-g15){#f12-or-41-05-2855}

![Visualized gene ontologies of *phospholipase C β1* and correlation-associated genes in genome-wide analysis. (A) Biological process, (B) cellular component and (C) molecular function.](OR-41-05-2855-g16){#f13-or-41-05-2855}

###### 

Overall survival and disease recurrence-free survival analysis plots of PLCB1-4. Overall survival analysis plots of (A) PLCB1, (B) PLCB2, (C) PLCB3 and (D) PLCB4. Disease recurrence-free survival analysis plot (E) PLCB1, (F) PLCB2, (G) PLCB3 and (H) PLCB4. PLCB, phospholipase C β; TPM, transcripts per million; HR, hazard ratio.

![](OR-41-05-2855-g17)

![](OR-41-05-2855-g18)

![Pearson correlation plots of PLCB1-4 genes. (A) PLCB1 vs. PLCB2; (B) PLCB3 vs. PLCB1; (C) PLCB4 vs. PLCB1; (D) PLCB3 vs. PLCB2; (E) PLCB4 vs. PLCB2; (E) PLCB3 vs. PLCB4. PLCB, phospholipase C β; TPM, transcripts per million.](OR-41-05-2855-g19){#f15-or-41-05-2855}

###### 

Prognostic analysis of PLCB genes for overall survival.

  Variable            Patients (n=212)   No. of events   MST (months)   HR (95% CI)            Crude P-value   HR (95% CI)                Adjusted P-value^[a](#tfn1-or-41-05-2855){ref-type="table-fn"}^
  ------------------- ------------------ --------------- -------------- ---------------------- --------------- -------------------------- -----------------------------------------------------------------
  *PLCB1*                                                                                                                                 
    Low expression    106                29              NA             Ref.                                   Ref.                       
    High expression   106                53              53             2.246 (1.426--3.536)   **\<0.001**     **2.100 (1.310--3.367)**   **0.002**
  *PLCB2*                                                                                                                                 
    Low expression    106                41              NA             Ref.                                   Ref.                       
    High expression   106                41              NA             0.902 (0.585--1.391)   0.641           1.041 (0.660--1.641)       0.863
  *PLCB3*                                                                                                                                 
    Low expression    106                36              NA             Ref.                                   Ref.                       
    High expression   106                46              NA             1.394 (0.900--2.159)   0.137           1.035 (0.659--1.625)       0.882
  *PLCB4*                                                                                                                                 
    Low expression    106                44              NA             Ref.                                   Ref.                       
    High expression   106                38              NA             0.877 (0.568--1.354)   0.555           0.870 (0.555--1.363)       0.534

P-values were adjusted for tumor size, cirrhosis, Barcelona Clinic Liver Cancer stage and α-fetoprotein; bold indicates significant P-values. Ref., reference value ([@b1-or-41-05-2855]); NA, not available; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; PLCB, phospholipase B.

###### 

Prognostic analysis of PLCB genes for recurrence-free survival.

  Variable            Patients (n=212)   No. of events   MST (months)   HR (95% CI)                Crude P-value   HR (95% CI)                Adjusted P-value^[a](#tfn2-or-41-05-2855){ref-type="table-fn"}^
  ------------------- ------------------ --------------- -------------- -------------------------- --------------- -------------------------- -----------------------------------------------------------------
  *PLCB1*                                                                                                                                     
    Low expression    106                46              NA             Ref.                                       Ref.                       
    High expression   106                70              26.9           **1.914 (1.318--2.781)**   **0.001**       **1.861 (1.273--2.271)**   **0.001**
  *PLCB2*                                                                                                                                     
    Low expression    106                59              36.0           Ref.                                       Ref.                       
    High expression   106                57              51.1           0.863 (0.599--1.243)       0.429           0.956 (0.654--1.398)       0.817
  *PLCB3*                                                                                                                                     
    Low expression    106                52              54.8           Ref.                                       Ref.                       
    High expression   106                64              29.9           **1.466 (1.015--2.118)**   **0.042**       1.244 (0.853--1.814)       0.257
  *PLCB4*                                                                                                                                     
    Low expression    106                59              46.3           Ref.                                       Ref.                       
    High expression   106                57              43.2           1.015 (0.705--1.461)       0.936           0.962 (0.664--1.395)       0.840

P-values were adjusted for gender, cirrhosis and Barcelona Clinic Liver Cancer stage. Ref., reference value ([@b1-or-41-05-2855]); MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; PLCB, phospholipase B. Bold indicates significant P-values.

###### 

Stratified analysis of *PLCB1* for overall survival and recurrence-free survival.

                    Overall survival   Recurrence-free survival                                                                                  
  ----------------- ------------------ -------------------------- ---------------------------- ----------- ---- ----- -------------------------- -----------
  Sex                                                                                                                                            
    Male            86                 89                         **1.967 (1.174--3.24)**      **0.010**   86   89    **1.877 (1.249--2.820)**   **0.002**
    Female          20                 17                         2.619 (0.711--9.652)         0.148       20   17    0.754 (0.168--3.382)       0.713
  Age (years)                                                                                                                                    
    ≤60             91                 92                         **2.252 (1.370--3.702)**     **0.001**   91   92    **1.736 (1.129--2.670)**   **0.012**
    \>60            15                 14                         0.850 (0.140--5.148)         0.860       15   14    2.043 (0.701--5.953)       0.191
  HBV                                                                                                                                            
    AVR-CC          20                 36                         1.987 (0.695--5.687)         0.200       20   36    1.486 (0.663--3.332)       0.336
    CC              86                 70                         **1.957 (1.114--3.438)**     **0.020**   86   70    **1.864 (1.166--2.979)**   **0.009**
  Tumor size (cm)                                                                                                                                
    ≤5              75                 62                         **2.100 (1.149--3.838)**     **0.016**   75   62    **1.627 (1.012--2.616)**   **0.045**
    \>5             30                 44                         1.790 (0.821--3.901)         0.143       30   44    **2.204 (1.049--4.629)**   **0.037**
  Cirrhosis                                                                                                                                      
    Yes             93                 102                        **1.922 (1.196--3.091)**     **0.007**   93   102   **1.678 (1.124--2.503)**   **0.011**
    No              13                 4                          476.586 (5.21E-12-4.36E16)   0.707       13   4     3.758 (0.379--37.311)      0.258
  Multinodular                                                                                                                                   
    Yes             21                 24                         1.399 (0.544--3.598)         0.487       21   24    1.186 (0.474--2.965)       0.716
    No              85                 82                         **2.662 (1.522--4.656)**     **0.001**   85   82    **2.163 (1.395--3.355)**   **0.001**
  AFP (ng/ml)                                                                                                                                    
    ≤300            68                 47                         **2.098 (1.097--4.015)**     **0.025**   68   47    **2.180 (1.307--3.635)**   **0.003**
    \>300           35                 59                         1.886 (0.934--3.806)         0.077       35   59    1.294 (0.710--2.359)       0.399
  BCLC stage                                                                                                                                     
    0               8                  12                         0.535 (0.033--8.559)         0.658       8    12    0.597 (0.097--3.665)       0.577
    A               79                 64                         **2.214 (1.210--4.051)**     **0.010**   79   64    **1.928 (1.200--3.097)**   **0.007**
    B               10                 12                         0.746 (0.225--2.478)         0.633       10   12    0.903 (0.310--2.627)       0.851
    C               9                  18                         2.746 (0.836--9.021)         0.096       9    18    2.370 (0.774--7.252)       0.131

Ref., reference value ([@b1-or-41-05-2855]); PLCB, phospholipase B; HR, hazard ratio; 95% CI, 95% confidence interval; HBV, hepatitis B virus; AVR-CC, acute viral replication-chronic carrier; CC, chronic carrier; AFP, AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer. Bold indicates significant P-values.

###### 

Joint-effect analysis of PLCB1 and AFP for overall survival and recurrence-free survival.

  A, Overall survival                                                                                                         
  ----------------------------- ---------------- ------------------ -------------- -------------- --------------------------- ------------------
  1                             Low              Low                18/68          NA             Ref.                        **0.008**
  2                             Low              High               32/82          NA             **2.162 (1.143--4.089)**    **0.018**
                                High             Low                                                                          
  3                             High             High               32/59          36.4           **4.382 (1.703--11.276)**   **0.002**
                                                                                                                              
  B, Recurrence-free survival                                                                                                 
                                                                                                                              
  Group                         AFP expression   PLCB1 expression   Events/total   MST (months)   Adjusted HR (95% CI)        Adjusted P-value
                                                                                                                              
  I                             Low              Low                29/68          NA             Ref.                        0.075
  II                            Low              High               50/82          40.1           **1.613 (1.019--2.555)**    **0.041**
                                High             Low                                                                          
  III                           High             High               37/59          23.0           **1.670 (1.012--2.755)**    **0.045**

Group 1, AFP low expression and PLCB1 low expression; Group 2, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group 3, AFP high expression and PLCB1 high expression; Group I, AFP low expression and PLCB1 low expression; Group II, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group III, AFP high expression and PLCB1 high expression. Ref., reference value ([@b1-or-41-05-2855]); PLCB, phospholipase B; AFP, α-fetoprotein; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval. Bold indicates significant P-values.

###### 

Enrichment results of gene ontologies and KEGG pathways of phospholipase B1 with genome-wide associated genes.

  Category             Term                                                                 Count   P-value    False discovery rate   Genes
  -------------------- -------------------------------------------------------------------- ------- ---------- ---------------------- -------------------------------------------------------------------------------------------------------------------
  Biological process   Oxidation-reduction process                                          11      1.15E-06   0.001521               FMO4, CBR1, MSRA, PLOD2, BLVRB, F8, SMOX, GRHPR, NDUFA10, HPD, HSD17B8
  Molecular function   Long-chain fatty acid-CoA ligase activity                              3     0.000399   0.455909               ACSL4, ACSL3, SLC27A5
  Cellular component   Extracellular exosome                                                16      0.000748   0.826682               NACA, FCER2, CAPZA1, FBP1, AXL, SPINK1, GRHPR, CBR1, MSRA, RPL7, PLOD2, BLVRB, SNRPB, ACSL4, PLCB1, HPD
  Biological process   Long-chain fatty acid metabolic process                                3     0.001186   1.559498               ACSL4, ACSL3, SLC27A5
  Cellular component   Cytosol                                                              17      0.001409   1.552995               CAPZA1, FBP1, ARHGAP28, TRIB3, SAE1, GRHPR, CBR1, MSRA, RPL7, NCAPG, BLVRB, SNRPB, SMOX, PLCB1, SNRPF, NUP43, HPD
  Cellular component   Endoplasmic reticulum membrane                                         7     0.012018   12.55815               FMO4, HMOX2, PLOD2, ACSL4, ACSL3, SLC27A5, HPD
  Cellular component   Actin cytoskeleton                                                     4     0.012886   13.40731               MSRA, SORBS2, NCAPG, CAPZA1
  Cellular component   U7 snRNP                                                               2     0.015645   16.05626               SNRPB, SNRPF
  Biological process   Heme catabolic process                                                 2     0.01697    20.28229               HMOX2, BLVRB
  Molecular function   Decanoate-CoA ligase activity                                          2     0.018337   19.08795               ACSL4, ACSL3
  Molecular function   Very long-chain fatty acid-CoA ligase activity                         2     0.02287    23.26214               ACSL4, SLC27A5
  Cellular component   U4 snRNP                                                               2     0.024478   24.04788               SNRPB, SNRPF
  Cellular component   Methylosome                                                            2     0.026674   25.92421               SNRPB, SNRPF
  Biological process   Cellular protein modification process                                  3     0.027107   30.50786               MSRA, PLOD2, SAE1
  Cellular component   Small nucleolar ribonucleoprotein complex                              2     0.028865   27.75428               SNRPB, SNRPF
  Biological process   Histone mRNA metabolic process                                         2     0.028919   32.20282               SNRPB, SNRPF
  Biological process   Positive regulation of nitric-oxide synthase biosynthetic process      2     0.031291   34.36424               CCL20, FCER2
  Molecular function   RNA binding                                                            5     0.036659   34.78158               RPL7, SNRPB, CPSF6, PAPOLG, SNRPF
  Cellular component   Intracellular ribonucleoprotein complex                                3     0.037507   34.57769               RPL7, SNRPB, CPSF6
  Cellular component   Small nuclear ribonucleoprotein complex                                2     0.037582   34.63438               SNRPB, SNRPF
  Cellular component   SMN-Sm protein complex                                                 2     0.037582   34.63438               SNRPB, SNRPF
  Cellular component   U1 snRNP                                                               2     0.041912   37.82519               SNRPB, SNRPF
  Biological process   Nuclear import                                                         2     0.043071   44.18227               SNRPB, SNRPF
  Cellular component   U12-type spliceosomal complex                                          2     0.056916   47.81769               SNRPB, SNRPF
  Biological process   Metabolic process                                                      3     0.063294   57.93576               GRHPR, ACSL4, ACSL3
  Biological process   Drug metabolic process                                                 2     0.063922   58.30767               FMO4, CBR1
  Biological process   Spliceosomal snRNP assembly                                            2     0.066211   59.63802               SNRPB, SNRPF
  Biological process   mRNA polyadenylation                                                   2     0.066211   59.63802               CPSF6, PAPOLG
  Biological process   Regulation of glucose transport                                        2     0.077575   65.68049               TRIB3, NUP43
  Biological process   Regulation of G-protein coupled receptor protein signaling pathway     2     0.091035   71.75149               RAMP3, PLCB1
  Biological process   Long-chain fatty-acyl-CoA biosynthetic process                         2     0.097693   74.37219               ACSL4, ACSL3
  KEGG pathway         PPAR signaling pathway                                                 3     0.031778   29.78018               ACSL4, ACSL3, SLC27A5
  KEGG pathway         Fatty acid biosynthesis                                                2     0.053251   45.0671                ACSL4, ACSL3
  KEGG pathway         Metabolic pathways                                                   10      0.058505   48.31368               CBR1, FBP1, GRHPR, ACSL4, PLCB1, NDUFA10, ACSL3, SLC27A5, HPD, HSD17B8

KEGG, Kyoto Encyclopedia of Genes and Genomes.
